<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01291459</url>
  </required_header>
  <id_info>
    <org_study_id>2009/HD/01</org_study_id>
    <nct_id>NCT01291459</nct_id>
  </id_info>
  <brief_title>Pilot Study of Maraviroc/Raltegravir for Naive HIV-1 Patients</brief_title>
  <acronym>NNNB</acronym>
  <official_title>Phase II Pilot Study of Simplification to Maraviroc - Raltegravir Dual Therapy After 6 Months of Maraviroc - Raltegravir - Tenofovir - Emtricitabine Quadruple Therapy in ARV Treatment-naive, HIV-1-infected Patients With CCR5- Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association Pour la Recherche en Infectiologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association Pour la Recherche en Infectiologie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background and Rationale&#xD;
&#xD;
      Raltegravir and Maraviroc, the first in class of 2 new families of antiretroviral drugs have&#xD;
      demonstrated a high potency in treatment experienced and naive patients. Both drugs appeared&#xD;
      well tolerated with low metabolic toxicity. No data are currently available concerning the&#xD;
      combination of these 2 drugs.&#xD;
&#xD;
      Hypothesis&#xD;
&#xD;
      Maraviroc + Raltegravir should be potent enough to maintain virological efficacy in naive&#xD;
      patients infected by CCR5 HIV-1 previously treated for 6 months with a&#xD;
      Maraviroc-Raltegravir-Tenofovir-Emtricitabine combination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
        -  To establish the ability of a Maraviroc-Raltegravir combination to maintain HIV-1 viral&#xD;
           load &lt; 50 copies/ml at week 48 in naive patients infected by CCR5 HIV-1, following an&#xD;
           initial 6 month phase of Maraviroc-Raltegravir-Tenofovir-Emtricitabine combination&#xD;
           (Intent to treat and strategy analysis)&#xD;
&#xD;
        -  To study CD4 progression from baseline to week 48&#xD;
&#xD;
        -  To study the time to virological failure during the simplification phase of the study&#xD;
           (from week 24 to week 48)&#xD;
&#xD;
        -  To study the proportion of patients with HIV RNA &lt; 50 copies/ml at each time point&#xD;
&#xD;
        -  To study the kinetics of viral load decrease from baseline to week 12&#xD;
&#xD;
        -  To study the kinetics of proviral DNA decrease from baseline to week 12, 24, 36 and 48&#xD;
&#xD;
        -  To study the clinical and biological tolerance of Maraviroc-Raltegravir combination&#xD;
           through week 48&#xD;
&#xD;
      Study Design/ Clinical Plan&#xD;
&#xD;
      Pilot, multicenter, national, uncontrolled study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV-1 viral load</measure>
    <time_frame>48 weeks</time_frame>
    <description>measure of HIV viral load at 48 weeks of treatment for all patients</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maraviroc/raltegravir/emtricitabine/tenofovir 24 weeks followed by Maraviroc/Raltegravir 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MVC/RAL/FTC/TDF followed by Maraviroc/Raltegravir</intervention_name>
    <description>MVC/RAL/FTC/TDF 24W followed by MVC/RAL until W48.</description>
    <arm_group_label>single arm</arm_group_label>
    <other_name>Maraviroc</other_name>
    <other_name>Raltegravir</other_name>
    <other_name>Emtricitabine</other_name>
    <other_name>Tenofovir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years old at the run-in visit&#xD;
&#xD;
          -  HIV-1 infection&#xD;
&#xD;
          -  Antiretroviral treatment-naive&#xD;
&#xD;
          -  CD4 ≥ 200 /mm3&#xD;
&#xD;
          -  HIV- RNA ≥ 1000 copies/ml&#xD;
&#xD;
          -  HIV-RNA ≤ 100,000 copies/ml&#xD;
&#xD;
          -  Antiretroviral therapy is indicated according to current guidelines&#xD;
&#xD;
          -  CCR5-tropic virus according to the Trofile ES® assayGeno2Pheno algorithm using a&#xD;
             predefined false positive rate of 20%&#xD;
&#xD;
          -  No significant NRTI, NNRTI or PI resistance mutation&#xD;
&#xD;
          -  Freely-given, written, informed consent obtained; the patient and investigator have&#xD;
             signed the consent form (by the latest on the day of the run-in visit and before&#xD;
             performing any examinations required by the trial)&#xD;
&#xD;
          -  Patient covered by a French national health insurance scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women of child-bearing potential not using effective contraception (barrier method)&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Patients under the age of 18 years&#xD;
&#xD;
          -  Patients deprived of liberty by a judicial or administrative, hospitalized patients&#xD;
             without consent, patients admitted to a health or social purposes other than research&#xD;
&#xD;
          -  Persons major subject of a measure of legal protection or unable to consent&#xD;
&#xD;
          -  Previous antiretroviral therapy (with the exception of post-exposure prophylaxis if&#xD;
             HIV serology is negative &gt; 3 months after the last dose of antiretroviral drugs)&#xD;
&#xD;
          -  CXCR4-tropic virus, dual/mixed-tropic virus or undetermined tropism on screening&#xD;
&#xD;
          -  Presence of significant NRTI, NNRTI or PI resistance mutation(s)&#xD;
&#xD;
          -  Infection or co-infection with HIV-2, or group O or N HIV-1&#xD;
&#xD;
          -  Acute phase of an opportunistic infection&#xD;
&#xD;
          -  Undergoing treatment for tuberculosis&#xD;
&#xD;
          -  Undergoing chemotherapy and/or radiotherapy for neoplastic disease&#xD;
&#xD;
          -  Decompensated cirrhosis (Child-Pugh class B or C)&#xD;
&#xD;
          -  HIV-HBV co-infection. Patients with HIV-HCV co-infection are permitted to participate&#xD;
             in the absence of decompensated cirrhosis (Child-Pugh class B or C), of&#xD;
             hepatocytolysis &gt; 3 times the upper limit of normal and if treatment for HCV during&#xD;
             the ensuing 12 months is not indicated. PAtients with occult HBV are excluded.(&#xD;
             positive AcHBc, negative AcHBs, negative AgHBs, positive HBV DNA)&#xD;
&#xD;
          -  Co-administration of prohibited treatments (see the SPCs of each product) Laboratory&#xD;
             parameters: Haemoglobin &lt; 7g/dl, neutrophil count &lt; 500/mm3, platelet count &lt;&#xD;
             50,000/mm3, creatinine clearance &lt; 50 ml/min, alkaline phosphatase, AST, ALT or&#xD;
             bilirubin ≥ 3 times upper limit of normal&#xD;
&#xD;
          -  Patient refuses to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent COTTE, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Cannes hosipital</name>
      <address>
        <city>CAnnes</city>
        <zip>06400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frejus hospital</name>
      <address>
        <city>Frejus</city>
        <zip>83608</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edourad Herriot hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Croix Rousse hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ste MArguerite Hospital</name>
      <address>
        <city>MArseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Conception hospital</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital l'Archet 1</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Louis Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pitie Salpetriere Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nord Hospital</name>
      <address>
        <city>St Etienne</city>
        <zip>42277</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>January 26, 2011</study_first_submitted>
  <study_first_submitted_qc>February 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2011</study_first_posted>
  <last_update_submitted>December 29, 2015</last_update_submitted>
  <last_update_submitted_qc>December 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Association Pour la Recherche en Infectiologie</investigator_affiliation>
    <investigator_full_name>Dr Laurent COTTE</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>naive patients</keyword>
  <keyword>maraviroc</keyword>
  <keyword>raltegravir</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 9, 2018</submitted>
    <returned>September 18, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

